Key insights
- Lexeo Therapeutics' shares rose 25% following positive interim data for its gene therapy LX2020. The therapy showed significant reductions in abnormal heart rhythms in patients with PKP2-ACM. The FDA indicated openness to using NSVT as a primary surrogate endpoint for accelerated approval, a key regulatory development. The company expects to finalize pivotal trial design in 2027.

Investing.com -- Lexeo Therapeutics (NASDAQ: LXEO) shares surged 25% on Monday after interim clinical trial results showed substantial reductions in abnormal heart rhythms among patients receiving its experimental gene therapy, while regulatory feedback provided a potential pathway toward accelerated approval.
Participants in the high-dose cohorts recorded an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) and a 44% mean reduction in premature ventricular contractions (PVCs) at the latest assessment, compared with baseline. Six of seven participants showed improvement in NSVT, while five of seven improved in PVC burden. Five also reported improvements in symptoms. Ten participants have been dosed in the trial in total, nine of them with at least 12 months of follow-up; the headline efficacy figures are from the seven high-dose participants.
"These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM," said CEO R. Nolan Townsend. "The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM."
The regulatory development could be significant for Lexeo. The FDA indicated it is open to the use of guideline-defined NSVT as a primary surrogate endpoint in a pivotal trial, potentially supporting an accelerated approval application. However, the final trial design remains subject to further discussions with regulators. Lexeo expects to finalize the pivotal study design in the first half of 2027 and initiate the study in the second half of 2027.
LX2020 was generally well tolerated, with no clinically significant complement activation or treatment discontinuations among the ten participants. Previously reported liver enzyme elevations in the high-dose cohorts were successfully managed under the trial protocol. One Grade 3 serious adverse event involving ventricular tachycardia occurred three months after dosing, which the company described as consistent with the natural progression of the disease.
Wall Street analysts welcomed the results. Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating, saying the 80% reduction in NSVT substantially exceeded the roughly 30% reduction associated with current pharmacological standard-of-care treatment and what she believed the market had been expecting. "We are buyers," Kluska said, adding that the findings significantly derisk the potential for accelerated approval.
Raymond James analyst Christopher Raymond raised his price target to $42 from $24, maintaining a Strong Buy rating. He described the results as "a better than best-case scenario," citing a 30% or greater NSVT reduction as the threshold that a high-volume PKP2-ACM specialist had previously identified as meaningful.
Separately, Lexeo reported a third-quarter net loss of $38.3 million, or $0.43 per share, compared with a loss of $20.3 million, or $0.33 per share, a year earlier. Research and development expenses more than doubled to $34.5 million, partly reflecting acquisition-related costs and a development milestone payment. The company ended September with $219.1 million in cash, cash equivalents and investments, which it expects to fund operations into 2028.
Original Article